Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease

Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.

Isometric double cube between white and black. Negotiation, diplomacy, cooperation, conflict and merging concept.
Merck & Co. is acquiring an autoimmune disease platform • Source: Shutterstock

Merck & Co., Inc. is building out its autoimmune disease capability with the $1.85bn acquisition of Pandion Therapeutics, Inc. announced on 25 February. The bulk of Merck & Co.'s recent string of deals has been in oncology, but this acquisition appears to balance the scale in a different therapeutic area.

A newly public company focused on the development of precision immune modulators targeting key immune control nodes, Pandion has a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immunological

More from Therapeutic Category